Skip to content

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Open access Aug 2026

Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives

The C-X-C motif chemokine receptor 4 (CXCR4)/C-X-C motif chemokine ligand 12 (CXCL12) axis drives immune exclusion in pancreatic ductal adenocarcinoma (PDA). Building on our preclinical data, we conducted the first stage of an open-label, single-arm phase 2 clinical trial combining CXCR4 inhibition (motixafortide), PD-...

A. Raufi, Edridge K. D'Souza, Michael S. May et al. · 0 citations
Review Sep 2026

Abstract A132: A Phase 2 Study to Investigate the Efficacy and Safety of Acoustic Cluster Therapy with Modified FOLFIRINOX in Patients with Locally Advanced and Borderline Resectable Pancreatic Cancer

Findings support continued evaluation of ACT as a strategy to enhance chemotherapy delivery and improve outcomes in borderline resectable or LAPC, and show no apparent effect on the expected safety profile of mFOLFIRINOX.

Erin Pierce, Ragnar Bendiksen, Amir Snapir et al. · 0 citations
Sep 2026

Abstract B108: CXCR4 inhibition reprograms immune checkpoint networks and enhances anti-tumor immunity in patient-derived pancreatic cancer organoid–PBMC co-cultures

A patient-specific ex vivo organoid model is developed to define CXCL12/CXCR4-mediated immune regulation and identify additional cellular and molecular targets to enhance antitumor efficacy and demonstrate that CXCR4 inhibition enhances immune-cell infiltration and activation, modulates checkpoint expression, and promo...

I. Pellicciotta, G. Manji, A. Raufi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.